NervGen Pharma Corp. NGEN
—
1.94
(0.08)
(3.96%)
as of 25 Sep
- Market cap
- $217.2M
- P/E
- 0.0×
Follow NGEN
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
1.12 | 1.16 |
Net Debt/EBITDA |
0.70 | 0.88 |
Debt/Assets |
0.04% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.70 | 0.44 |
Capex/Depreciation |
0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 |
| 0.00% | (1,445.47%) | |
| 0.00% | (204.82%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(1,136.82%) | (1,438.09%) |
Average Days of Receivables |
0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.18) | (0.19) |
Cash per Share |
0.19 | 0.22 |
Shareholders Equity per Share |
0.03 | 0.03 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.03 | 0.03 |
Free Cash Flow |
(12.29) | (13.96) |
Working Capital |
1.54 | 2.20 |
Net Current Asset Value |
1.54 | 2.20 |
| Other line items | ||
Quick Ratio |
1.05 | 1.12 |
Depreciation/Fixed assets |
0.00 | 0.00 |
Cash ROIC |
(84.42%) | (76.30%) |
Accounts Receivable Turnover |
— | 0.00 |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.18) | (0.19) |
Capex per Share |
0.00 | 0.00 |
Average Receivables |
— | 0.18 |
Average Payables |
— | 3.47 |
Average Assets |
— | 15.42 |
Average Common Equity |
— | 2.18 |
Net Profit Margin |
0.00% | 0.00% |
Columns are period end dates